Can the Medical Model Expand for Psychedelic Medicine?

For decades, modern medicine has developed remarkably effective ways to evaluate new treatments.

The FDA's finalized guidance for psychedelic drug development reinforces the importance of this framework. Clear expectations for trial design, participant safety, psychological support, and outcome assessment help create the scientific rigor necessary for psychedelic medicine to earn public trust.

But the guidance also invites a larger question.

Can a medical model developed primarily to evaluate conventional pharmacologic treatments fully capture therapies whose potential benefits extend beyond symptom reduction?

This is a critical question because psychedelic therapies may challenge us to think more broadly about what healing actually looks like.

A Milestone Worth Recognizing

The FDA's finalized guidance represents an important step for the field.

Psychedelic medicine has often been discussed through headlines, speculation, and polarized opinions. Clear regulatory guidance helps move the conversation toward evidence.

It encourages rigorous study design. It strengthens participant protections. It improves consistency across clinical trials.

Most importantly, it communicates that psychedelic therapies deserve serious scientific scrutiny.

Good regulation builds trust. Patients deserve that trust. Clinicians deserve that trust. The field deserves that trust.

Psychedelics Are Not Typical Medications

At the same time, psychedelic therapies differ from nearly every medication currently used in psychiatry.

Many psychiatric medications primarily target symptom reduction. Psychedelic therapies have the ability to reduce symptoms as well, but participants often describe additional changes that are much harder to quantify.

They may report shifts in perspective, changes in relationships, greater psychological flexibility, different ways of understanding themselves, renewed meaning or purpose, spiritual experiences, or profound emotional processing. Sometimes they report none of those things.

The point is not that these experiences occur universally. The point is that they may become part of the therapeutic process in ways conventional drug development has rarely needed to evaluate.

What Should We Measure?

Psychiatric research has appropriately relied on validated symptom scales for decades. Those tools remain essential.

If a treatment claims to improve depression, anxiety, post-traumatic stress disorder, or a substance use disorder, we should measure those outcomes carefully.

But symptom scales may not capture everything patients describe after psychedelic treatment.

What if someone reports less depression while also reconnecting with family? What if someone develops greater emotional openness, returns to work, repairs relationships, or finds renewed purpose despite only modest changes on a rating scale?

Conversely, what if someone has a profound subjective experience but little meaningful improvement in daily functioning?

Both situations matter clinically.

The challenge is determining how to measure outcomes that are deeply subjective while maintaining rigorous scientific standards.

Efficacy, Safety, and Implementation

Three questions should guide the clinical interpretation of psychedelic research.

Does it work? Is it reasonably safe? Can real clinicians realistically deliver it to real patients?

The third question often receives less attention than it deserves.

As a psychiatrist and psychedelic therapist, I have become increasingly convinced that implementation may determine whether promising research ultimately benefits patients.

Psychedelics generally appear to have favorable safety profiles when administered within appropriate screening and clinical settings. The greater practical challenge is that many people seeking them are medically and psychiatrically complex.

They may have treatment-resistant illness, polypharmacy, trauma histories, medical comorbidities, diagnostic uncertainty, substance use concerns, and longitudinal psychiatric needs.

Because of this, a thoughtful, nuanced approach to psychedelic therapy should be the rule, not the exception.

Careful screening, diagnostic clarity, medication management, preparation, psychological support, integration, and longitudinal follow-up are not peripheral to treatment. They are part of treatment.

The Limits of Conventional Trial Design

Psychedelic trials face familiar scientific questions and several unusual ones.

Blinding is difficult when a participant experiences an obvious change in consciousness. Expectancy can shape outcomes. Psychological support may be necessary for safety, but it can also complicate efforts to isolate the effect of the drug. Acute symptom improvement may be clear while durability remains uncertain.

These challenges do not make rigorous trials impossible. They make thoughtful trial design even more important.

The field needs careful comparison groups, transparent reporting, long-term follow-up, robust adverse-event monitoring, and outcomes that include function as well as symptoms.

It also needs humility about what any single study can establish.

Could Regulation Become More Multidisciplinary?

This raises another possibility.

The question is not whether scientific rigor should change. The question is whether regulatory systems could benefit from broader expertise alongside traditional review.

That expertise might include psychiatrists, psychologists, psychotherapists, neuroscientists, clinical trial investigators and therapists, bioethicists, implementation scientists, and experienced psychedelic clinicians.

It should also include Indigenous knowledge holders and cultural practitioners whose traditions have informed psychedelic healing for generations.

None of these perspectives replaces evidence. They can help regulators ask better questions and interpret evidence in context.

They may offer valuable insight into preparation, integration, therapeutic context, functional outcomes, set and setting, and the realities of delivering psychedelic care beyond research settings.

The goal is not to create a weaker or separate standard for psychedelics. The goal is to make sure our scientific questions are broad enough to study these therapies responsibly.

Honoring Indigenous Foundations

Modern psychedelic research did not emerge in isolation.

Long before randomized controlled trials existed, Indigenous and ancestral communities developed sophisticated traditions surrounding psychedelic healing.

Those traditions emphasized preparation, relationship, ceremony, community, intention, responsibility, and meaning.

Modern clinical research has a different role. It can establish safety, efficacy, reproducibility, and regulatory confidence within contemporary healthcare systems. It may improve access.

These approaches need not compete.

Modern science can expand understanding without portraying itself as replacing the cultures and knowledge systems that carried these practices across generations.

Expanding Rather Than Abandoning the Medical Model

The future of psychedelic medicine should not become a choice between scientific rigor and tradition. Nor should it become a choice between regulation and innovation.

The more interesting possibility is integration.

Imagine a medical model that continues to value randomized trials, careful safety monitoring, standardized outcome measures, and regulatory oversight while becoming more capable of evaluating therapies that influence consciousness, relationships, meaning, and lived experience.

Good regulation creates trust. That principle should not change.

The question is whether psychedelic medicine invites us to expand the medical model rather than simply applying it exactly as it exists today.

I do not know the answer. I suspect none of us do.

But asking the question thoughtfully may be one of the most important contributions this field can make.

The future of psychedelic medicine may depend less on choosing between science and tradition than on bringing together the strengths of modern medicine, careful regulation, psychotherapy, neuroscience, Indigenous wisdom, ethics, and real-world clinical experience.

Psychedelic medicine deserves rigorous regulation. It may also deserve a regulatory framework that recognizes these therapies are unlike any medicines that have come before them.

If we can hold both ideas at once, we may not only improve psychedelic medicine. We may improve medicine itself.